An in vivo CAR enhancer, explained to the business development teams it is meant for: the five multipliers, the clinical evidence, and how a partner's vector could fit into the approach.
A partnership film for an anti-CSF3 antibody in idiopathic pulmonary fibrosis, shown only to the client and the partners they choose.
A mechanism explainer for an oral, first-in-class PON2 modulator in early Parkinson's disease, from the inner mitochondrial membrane to the Phase 2a data.
An investor-focused film introducing PN-101, mitochondria isolated from umbilical cord stem cells and given as a single intravenous dose: the platform, its manufacturing and the pipeline.
A mechanism film for NT-101, a peptide eye drop for wet AMD that has to reach the back of the eye, shown only to the client and the partners they choose.
How a molecule found by its effect on living cells gets the name of the protein it binds, and how that platform led to a drug in the clinic. A sample made from public sources.
A dual EP2/EP4 antagonist aimed at the PGE2 signal that lets tumours regrow after chemotherapy or radiation. A sample made from public sources.
A molecular glue that sends HSP47, the chaperone behind scar collagen, to the cell's own recycler, for hypertrophic scars. A sample made from public sources.
From microbe-based medicine to a shuttle across the blood-brain barrier: LISCure's platform and its clinical programme. A sample made from public sources.
A platform for antibody-mediated autoimmune disease that lowers pathogenic antibodies without depleting B cells. A sample made from public sources.
A first-in-class antibody that captures ONCOKINE-2, the factor tumours secrete to hold T cells back, so the T cells go back to work.
A partnership film presenting vutiglabridin, an oral PON2 modulator, as a partner for GLP-1-based obesity therapy, shown only to the partners Glaceum chooses.
A film or a series of films built around your next milestone. What it covers is agreed with you before work begins.
Your story evolves with every data readout, conference and funding round. We keep your films and presentation decks up to date throughout the term, in one consistent visual style.
Ongoing Partnership, plus a redesigned website built around your science, so every touchpoint with potential partners speaks the same language.
We have received your inquiry and will reply within one business day from contact@vanitaslab.com.
Yes. We sign an NDA before you share confidential material. It is kept only on our own machines and in your password-protected workspace, and only the team on your project can see it.
No. We make your science easier to understand while keeping it accurate: every figure and claim stays as your source states it, and the final sign-off on the science is yours.
You do. Copyright in the final film passes to you on full payment, for business use with no limit of time or territory. We show it as our work only with your written permission.
By scope, agreed in conversation and fixed in a quote before work begins.